These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7470626)

  • 1. Quantitative measurement of C3 activation at polymer surfaces.
    Herzlinger GA; Bing DH; Stein R; Cumming RD
    Blood; 1981 Apr; 57(4):764-70. PubMed ID: 7470626
    [No Abstract]   [Full Text] [Related]  

  • 2. Schistosoma mansoni: complement and cercarial tail loss during in vitro transformation.
    Greenblatt HC; Eveland LK; Morse SI
    Exp Parasitol; 1979 Aug; 48(1):100-8. PubMed ID: 456460
    [No Abstract]   [Full Text] [Related]  

  • 3. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
    Cooper PD; Sim RB
    Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the mechanism of haemopoietic stem cell (CFUs) mobilization. A role of the complement system.
    Wilschut IJ; Erkens-Versluis ME; Ploemacher RE; Benner R; Vos O
    Cell Tissue Kinet; 1979 May; 12(3):299-311. PubMed ID: 476778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of complement activation in cell adhesion to polymer blood contact surfaces.
    Herzlinger GA; Cumming RD
    Trans Am Soc Artif Intern Organs; 1980; 26():165-71. PubMed ID: 7245476
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternate complement pathway in porcine sera: lysis of guinea pig erythrocytes.
    Renshaw HW; Gilmore RJ
    Comp Immunol Microbiol Infect Dis; 1980; 3(4):473-84. PubMed ID: 7471719
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of C3 depletion on the genesis of thrombocytopenia induced in rats by Erysipelothrix rhusiopathiae.
    Nakato H; Shinomiya K; Mikawa H
    Scand J Haematol; 1986 Jul; 37(1):18-24. PubMed ID: 3764331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence, augmented adherence, and aggregation of polymorphonuclear leukocytes.
    McGillen JJ; Phair JP
    J Infect Dis; 1979 Jan; 139(1):69-73. PubMed ID: 374638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESR spectra of normal human serum after treatment with complement activating agents.
    Bartolotta A; Brai M; Messina M; Indovina PL
    Z Naturforsch C Biosci; 1980; 35(9-10):844-7. PubMed ID: 6255698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.
    van Dam AP; Hack CE
    Immunology; 1987 Jun; 61(2):105-10. PubMed ID: 3596635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of cobra venom factor-induced depletion of serum C3 in eight different strains of mice.
    Finnie JA; Stewart RB; Aston WP
    Dev Comp Immunol; 1981; 5(4):697-701. PubMed ID: 6797851
    [No Abstract]   [Full Text] [Related]  

  • 13. Hereditary C5 deficiency in man. III. Studies of hemostasis and platelet responses to zymosan.
    Breckenridge RT; Rosenfeld SI; Graff KS; Leddy JP
    J Immunol; 1977 Jan; 118(1):12-6. PubMed ID: 830743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged complement activation in mice.
    Simpson IJ; Moran J; Evans DJ; Peters DK
    Kidney Int; 1978 Jun; 13(6):467-71. PubMed ID: 713282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation during rejection in experimental intestinal transplantation.
    Soin AS; Pino-Chavez G; Chavez-Cartaya R; Jamieson NV; White DJ; Friend PJ
    Transplant Proc; 1997 May; 29(3):1811-2. PubMed ID: 9142282
    [No Abstract]   [Full Text] [Related]  

  • 17. Key role of complement activation and platelet-activating factor in exudate formation in zymosan-induced rat pleurisy.
    Imai Y; Hayashi M; Oh-ishi S
    Jpn J Pharmacol; 1991 Oct; 57(2):225-32. PubMed ID: 1812301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of iodipamide on human C3 and factor B in vitro.
    Durda PJ; Pagano RJ; Bauman N; Brockman JA
    J Allergy Clin Immunol; 1982 Nov; 70(5):353-60. PubMed ID: 6922882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble and particulate activators of complement and granulomatous pulmonary reactions.
    Pearson DJ; Green FH; Mentnech SM
    Clin Allergy; 1981 Mar; 11(2):111-9. PubMed ID: 6972274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of large C3 fragments as an index of complement activation in mice. II. In vivo studies.
    Lulé J; Fournié GJ; Conté JJ
    Complement; 1984; 1(2):103-7. PubMed ID: 6399880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.